Company Overview and News

Alcidion Group deploys unique clinical messaging solution for Monash Health

Alcidion Group Ltd (ASX:ALC) has achieved a successful production deployment of its clinical messaging technology, Smartpage, at the Monash Medical Centre and Monash Children’s Hospital in Melbourne.

Health: Game-changing research gives new hope to patients with cancer and other diseases

BIG money, big science, big building — but for South Australians in dire need, the biggest deal coming to North Tce is a whiz-bang machine that can destroy inoperable cancers.

Alcidion Group shares rise on securing major hospital contract

Alcidion Group (ASX:ALC) has won a NZ$1.6 million contract with the MidCentral District Health Board in New Zealand to utilise Alcidion’s technology across its public hospital facilities.

Alcidion Group wins hospital informatics contract with Western Health

Alcidion Group (ASX:ALC) has signed a contract to deploy its hospital information system across three public hospitals of Western Health, in the western suburbs of Melbourne.

Alcidion Group and FUJIFILM deploys intelligent hospital system

Alcidion Group (ASX:ALC) and FUJIFILM have completed the delivery of intelligent Cardiovascular Information System (iCVIS) to Sunshine Coast University Hospital in Queensland, Australia.

Alcidion Group Ltd signs $2.35M deal with Western Health

Alcidion Group Ltd (ASX:ALC) has signed a $2.35 million agreement with Western Health to utilise its electronic patient records platform – Miya, across Western Health’s three facilities in Victoria. Western Health employs 6,500 staff across three acute public hospitals. Alcidion’s Miya platform will provide all the necessary data to manage patient care, from the emergency department through to the hospital wards.

Alcidion Group Ltd unifies electronic medical records for Tasmanian Government

Alcidion Group Ltd (ASX:ALC) is a leading provider of clinical decision support systems, including patient flow software, mobile EMR and outpatient solutions.

Alcidion Group Ltd and FUJIFILM have cardiovascular system contract win

Alcidion Group Ltd (ASX:ALC) is a leading provider of clinical decision support systems, including patient flow software, mobile EMR and outpatient solutions.

Appendix 4C - March Quarterly


Becoming a substantial holder


Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...